Inhibidores selectivos de la recaptación de serotonina (ISRS) para la recuperación del accidente cerebrovascular
Información
- DOI:
- https://doi.org/10.1002/14651858.CD009286.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 14 noviembre 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Accidentes cerebrovasculares
- Copyright:
-
- Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Dr Mead, Dr Hackett and Professor Hankey wrote the protocol. Dr Kutlubaev and Dr Lee read the protocol and approved it. All authors contributed to the searches, or selection of trials or data extraction, as indicated in the text. Dr Mead performed the analyses.
Sources of support
Internal sources
-
None, Not specified.
External sources
-
Stroke Research Network, UK.
Stroke Research Network in England provided some financial support to the Cochrane Stroke Group for assistance with the searches
-
Scotland, Not specified.
Scottish Stroke Research Network provided some funding to the Cochrane Stroke group for assistance with the searches
Declarations of interest
Gillian Mead, Maree Hackett and Graeme Hankey are co‐principal investigators on the planned FOCUS trial (Fluoxetine or control under supervision) in the UK and the AFFINITY (Assessment of fluoxetine in stroke recovery) trial in Australia designed to assess the impact of fluoxetine on disability and dependency after stroke. These trials fulfil our inclusion criteria.
Acknowledgements
We are grateful to Brenda Thomas for her assistance in devising the search strategy, and to the editorial and peer reviewers Peter Langhorne, Brenda Thomas, Ashma Krishnan and Robert Robinson. We are grateful to Ms Maureen Harding for assisting to retrieve papers. We are grateful to Dr Maria Corretge for translating an Italian paper that was subsequently not eligible, and to Dr William Whitely for assistance with extracting data from a paper written in German. Dr Matthew Harris performed citation searches for three papers. We are grateful to Professor Maarten IJzerman for responding to our request for further information about the flu2066 and flu 2008 trials.
We are grateful to the peer reviewers (Peter Langhorne, Brenda Thomas, Andrew Herxheimer, Craig Anderson, Ashma Krishan) for their most helpful comments, and also to Dr Raghda Rashad who provided feedback from a consumer perspective.
Version history
| Published | Title | Stage | Authors | Version |
| 2021 Nov 15 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery | Review | Lynn A Legg, Ann-Sofie Rudberg, Xing Hua, Simiao Wu, Maree L Hackett, Russel Tilney, Linnea Lindgren, Mansur A Kutlubaev, Cheng-Fang Hsieh, Amanda J Barugh, Graeme J Hankey, Erik Lundström, Martin Dennis, Gillian E Mead | |
| 2019 Nov 26 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery | Review | Lynn A Legg, Russel Tilney, Cheng‐Fang Hsieh, Simiao Wu, Erik Lundström, Ann‐Sofie Rudberg, Mansur A Kutlubaev, Martin Dennis, Babak Soleimani, Amanda Barugh, Maree L Hackett, Graeme J Hankey, Gillian E Mead | |
| 2012 Nov 14 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery | Review | Gillian E Mead, Cheng‐Fang Hsieh, Rebecca Lee, Mansur A Kutlubaev, Anne Claxton, Graeme J Hankey, Maree L Hackett | |
| 2011 Nov 09 | Selective serotonin reuptake inhibitors (SSRIs) for stroke | Protocol | Gillian E Mead, Graeme J Hankey, Mansur A Kutlubaev, Rebecca Lee, Matthew Bailey, Maree L Hackett | |
Differences between protocol and review
We had planned to search the Organon and Wyeth pharmaceutical websites, but when the searches were done, these websites no longer existed. We decided to search the Lundbeck website as this company makes citalopram.
We had planned to search www.ClinicalStudyResults.org, but this was removed from the Internet in 2011.
We stated that we would include trials in which patients were recruited within three months of stroke onset. However, when we started our searches, we identified several trials in which patients had been recruited after three months. In order to ensure that our review provides a complete as possible picture about the role of SSRIs for stroke recovery, we decided to include trials in which the mean time since stroke onset was less than one year, and to perform subgroup analyses to explore the effect of time since onset on effect sizes. This decision was made before any data extraction and analysis had been performed.
We stated that two review authors would independently scrutinise the full‐text articles retrieved from the searches, but this was not possible for the main MEDLINE and EMBASE searches because of the large number of full texts retrieved; for these searches, one experienced review author (GM) scrutinised the full texts.
We also stated that two review authors would extract data. Several of our included trials had already been included in other Cochrane reviews led by Dr Hackett, one of our review authors. For these trials, only one additional review author extracted data and checked this against the data extraction that had previously been performed for the previous reviews.
We had not anticipated such as large number of Chinese studies. An additional review author joined the team to perform data extraction for these Chinese papers, but we could not find a second independent reviewer who was sufficiently fluent in Chinese to perform data extraction.
We had intended to use random‐effects models only if there was evidence of statistical heterogeneity. Following editorial review, we use random‐effects models for all our analyses.
We extracted data on sources of funding, and included this as part of risk of bias assessment.
